Evidence map›Paper›PMID 31787814›Full record

ArticleBioinformation2019

Molecular docking analysis of flavonoid compounds with HIV-1 Reverse transcriptase for the identification of potential effective inhibitors.

My Abdelaziz El Alaoui, Souad El Fartah, Najwa Alaoui, El Mostapha El Fahime, Amar Habsaoui

Open access · hybridAbstract read
In one paragraph

Article in Bioinformation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

My Abdelaziz El AlaouiFunctional Genomic Platform, UATRS, Center for Scientific and Technical Research [CNRST], ZIP 10000 Rabat, Morocco.
Souad El Fartahengineering and environment laboratory, Modeling and Application LIMEMA, Faculty of Science - University Ibn Tofail ,Kenitra .B.P 133 Kenitra 14000, Morocco.
Najwa AlaouiResearch Team in Molecular Virology and Oncobiology, Faculty of Medicine and Pharmacy, University Mohammed V in Rabat, Av. Mohamed Belarbi El Alaoui, ZIP 6203, Rabat, Morocco.
El Mostapha El FahimeFunctional Genomic Platform, UATRS, Center for Scientific and Technical Research [CNRST], ZIP 10000 Rabat, Morocco.
Amar Habsaouiengineering and environment laboratory, Modeling and Application LIMEMA, Faculty of Science - University Ibn Tofail ,Kenitra .B.P 133 Kenitra 14000, Morocco.
Mohammed V University · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is of interest to elucidate the binding mode analysis of 18 sulphonated flavones in the non nucleoside inhibitory binding pocket of the HIV-1 reverse transcriptase (PDB ID: 1RTD). We further compared them with the known Non Nucleosidic Reverse Transcriptase Inhibitors (NNRTI) drug molecules such as delaviridine, nevirapine and etravirine. Molecular docking studies of sulphonated flavones were performed in the binding pocket of reverse transcriptase using the PatchDock server. The flavones have different binding energies with RT and the atomic contact energy (ACE) value of sulfonated flavones range from-389 to-231 Kcal/mol while docking of the commercialized NNRTI showed the ACE value range from -486 to -224 Kcal/mol. This shows that most sulfonated flavones have ACE similar to the known NNRTI. Thus, seven compounds (FS-6, FS-7, FS-8, FS-9, FS-14, FS-15, FS-17) were reported as potent, selective, orally bio available, and nontoxic lead based on ADMET screening and effective binding analysis in the active site of the reverse transcriptase (PDB ID: 1RTD) for further consideration. We further document that compounds (FS-1, FS-10, FS-4 and FS-12) have unfavorable binding features to be considered as leads.

Indexed as

Drug designFlavonoidReverse Transcriptase

Identifiers

PMID31787814
PMCPMC6859701
OpenAlexW2983520905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.